Fri, Oct 24, 2014, 4:41 AM EDT - U.S. Markets open in 4 hrs 49 mins

Recent

% | $
Quotes you view appear here for quick access.

Navidea Biopharmaceuticals, Inc Message Board

  • ontopofitall4u ontopofitall4u Mar 8, 2013 11:05 PM Flag

    We will have to wait until next week to see if this run is for real

    or the shorts just want to have a larger margin to play with. I certainly hope that last article, that was full of lies, is the end of the manipulation but with 18 million shares short, I will n ot believe anything until Europen approval and/or better yert, FDA approval is given. I just wish the head and neck cancer study was finished and put on the berner for FDA to expand the label. They are many more catalyst to come with NAVB and do not be surprised to see that $6-$7 is not the top price after approval. Look at ARNA and SOMX, they went from $3.20 before approval to $6.50 after approval and both were driven up to over $10 before settling back around $8. SOMX tanked bad when they could not get a partner or distributor but the price right after approval was HYPED up over $10.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Agreed.

      The intraday high this year is $3.42, which occurred on both 2/1 and 2/4. If we can close above that I may begin to believe that the shorts are in retreat.

      Sentiment: Hold

      • 2 Replies to dmj3430
      • I expect that NAVB will see at least 3.43 next week. Beyond that, we will see.

        GLTA.

      • dmj: as Techread posted more cojently than i ever could, the shorts are for(at this time) the most part institutional longs hedging their long position up/until fda approval/additional catalysts executed/revenues from sales and possible partners(developmental/distribution). as Techread laid out the short position may actually not decrease after lymphoseek approval but rather languish unti revenues are a reality/exected future catalysts per the timeline). the tell(inmho) will be the institutional position in terms of size/% and the growth post said approval/revenue. all inmho and being augmented by Techreads analysis per my ability to correctly interpret his analysis. GLTALs!

        Sentiment: Buy

 
NAVB
1.40+0.04(+2.94%)Oct 23 4:05 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Infinera Corporation
NasdaqGSThu, Oct 23, 2014 4:00 PM EDT
Microsoft Corporation
NasdaqGSThu, Oct 23, 2014 4:00 PM EDT